Yurina Yamaya

Dr. Yurina Yamaya

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TKTsukasa Kuwana
Tsukasa Kuwana
Kosaku KinoshitaKosaku Kinoshita
Kosaku Kinoshita
YYYurina Yamaya
Yurina Yamaya
KTKen Takahashi
Ken Takahashi
JYJunko Yamaguchi
Junko Yamaguchi
ITImai Toru
Imai Toru
Background/Objectives: The 28-day mortality rate for septic shock is high, necessitating rapid and effective empiric antimicrobial therapy. This study investigates whether the rate of catecholamine dose reduction in septic shock can indicate bacterial susceptibility to initial antimicrobial therapy. Methods: This retrospective observational study involved 108 adult patients with bacteraemia and septic shock admitted at the intensive care unit of Nihon University Itabashi Hospital between January 2017 and December 2023. They were classified into the Susceptible or Resistant group based on the bacteria’s susceptibility to the initial empiric antimicrobial therapy. Catecholamine dosages were converted to norepinephrine equivalent (NEE) scores, with the time course from peak to end of administration measured at NEE reductions. Results: Of the 108 patients, 94 were in the Susceptible group and 14 in the Resistant group. The Susceptible group showed faster reductions in catecholamine doses: time to reduce the dose from the maximum NEE to 25% was 19 vs. 49.5 hours (p = 0.0057); and 0%, 29 vs. 54 hours (p = 0.0475). Conclusions: In septic shock with bacteraemia, faster catecholamine dose reduction indicates bacterial susceptibility to initial empiric antibiotics. This reduction rate can serve as an early clinical indicator of appropriate initial empiric therapy.

4 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TKTsukasa Kuwana
Tsukasa Kuwana
Kosaku KinoshitaKosaku Kinoshita
Kosaku Kinoshita
YYYurina Yamaya
Yurina Yamaya
KTKen Takahashi
Ken Takahashi
JYJunko Yamaguchi
Junko Yamaguchi
ITImai Toru
Imai Toru
Background/Objectives: The 28-day mortality rate for septic shock is high, necessitating rapid and effective empiric antimicrobial therapy. In this study, we investigate whether the rate of catecholamine dose reduction in septic shock can indicate bacterial susceptibility to initial antimicrobial therapy or not. Methods: This retrospective observational study involved 108 adult patients with bacteraemia and septic shock admitted to the intensive care unit of Nihon University Itabashi Hospital between January 2017 and December 2023. They were classified into the Susceptible or Resistant groups based on the bacteria’s susceptibility to the initial empiric antimicrobial therapy. Catecholamine dosages were converted to norepinephrine equivalent (NEE) scores, with the time course from the peak to the end of administration measured at NEE reductions. Results: Of the 108 patients, 94 were in the Susceptible group and 14 in the Resistant group. The Susceptible group showed faster reductions in catecholamine doses: the time to reduce the dose from the maximum NEE to 25% was 19 vs. 49.5 h (p = 0.0057), and to 0%, it was 29 vs. 54 h (p = 0.0475). The time to reduce the dose from the maximum NEE to 75% was 8 vs. 12.5 h (p = 0.0733), and to 50% it was 13 vs. 21.5 h (p = 0.1081). Conclusions: In septic shock with bacteraemia, a faster catecholamine dose reduction indicates bacterial susceptibility to the initial empiric antibiotics. This reduction rate can serve as an early clinical indicator of the appropriate initial empiric therapy.

15 July 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
YYYurina Yamaya
Yurina Yamaya
TKTsukasa Kuwana
Tsukasa Kuwana
Kosaku KinoshitaKosaku Kinoshita
Kosaku Kinoshita
KTKen Takahashi
Ken Takahashi
HNHayato Nakabayashi
Hayato Nakabayashi
ITImai Toru
Imai Toru
Background/Objectives: Septic shock carries high mortality. Although guidelines recommend early empiric antibiotics, early identification of the infection source and selection of appropriate initial antibiotic therapy remain challenging. This study examined whether vasopressor trajectories, quantified as norepinephrine equivalent (NEE), differed according to initial antimicrobial susceptibility and concordance between presumed and final infection sources. Methods: This single-center retrospective observational study included adults with Sepsis-3 septic shock admitted to the intensive care unit between 2017 and 2023. Patients were classified into the appropriate-management group when the initial antibiotic therapy covered the subsequently identified causative pathogen and the initially presumed infection source was concordant with the final infection source; all others were classified into the inappropriate-management group. Primary outcomes were Max NEE duration and the times from Max NEE to 75%, 50%, 25%, and discontinuation of NEE. Results: Among 132 patients analyzed, 101 were classified into the appropriate-management group and 31 into the inappropriate-management group. Max NEE duration was shorter in the appropriate-management group (median (IQR), 4 (2–7) h vs. 6 (3–20) h; p = 0.0100) and remained shorter after excluding deaths during the Max NEE period (n = 119; 6 (2–11) h vs. 11 (5–14) h; p = 0.0314). Time to NEE reduction from Max NEE was shorter in the appropriate-management group, with significant differences at 75% (7 (4–13) h vs. 13 (9–23) h; p = 0.0066) and 25% (19 (13–29) h vs. 31 (16–46) h; p = 0.0247). Conclusions: Prolonged Max NEE duration and delayed NEE reduction were associated with inadequate coverage by initial antibiotic therapy or discordant infection source identification in this selected cohort. Vasopressor trajectories may help prompt reassessment of antibiotic therapy and infection source evaluation.

15 January 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
TKTsukasa Kuwana
Tsukasa Kuwana
Kosaku KinoshitaKosaku Kinoshita
Kosaku Kinoshita
YKYuma Kanai
Yuma Kanai
YYYurina Yamaya
Yurina Yamaya
KTKen Takahashi
Ken Takahashi
ITImai Toru
Imai Toru
Background/Objectives: Sepsis is a life-threatening condition associated with high mortality. Optimal dosing strategies for β-lactam antibiotics in sepsis remain controversial, particularly in patients with renal impairment. Cefepime (CFPM) is widely used as empiric therapy; however, its appropriate initial dosing in critically ill patients is unclear. This study aimed to evaluate whether high-dose CFPM administration during the first 48 h improves survival in patients with sepsis, irrespective of renal function. Methods: This single-center, retrospective, observational study included adult intensive care unit (ICU) patients with sepsis who received CFPM as initial therapy between January 2017 and December 2024. Patients were categorized into High-dose (12 g within 48 h; 2 g every 8 h) and Low-dose (<12 g/48 h) groups. The primary outcome was ICU survival. To address confounding, inverse probability of treatment weighting (IPTW) based on serum creatinine was applied, with sensitivity analyses using 1% trimmed and stabilized IPTW. Results: Of 122 eligible patients, 84 were analyzed (High-dose: n = 27; Low-dose: n = 57). After IPTW adjustment, high-dose CFPM was significantly associated with improved ICU survival (odds ratio [OR] 5.43, 95% confidence interval [CI] 1.60–18.39, p = 0.0066). This association remained consistent in the 1% trimmed IPTW analysis (OR 4.07, 95% CI 1.19–13.97, p = 0.0256). Stabilized IPTW yielded a similar effect estimate, though without statistical significance (OR 5.43, 95% CI 0.72–41.16, p = 0.1017). Overall, results were consistent in direction and magnitude across models. Conclusions: High-dose CFPM administration during the initial 48 h was associated with improved ICU survival in patients with sepsis, independent of renal function.